| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Joseph Frattaroli last filed a Form 4 in March 2023, as Chief Financial Officer at IKT. Joseph Frattaroli's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 48,091 shares of IKT. Net of sales, the IKT filings show accumulation of 3,948 shares.
Joseph Frattaroli has 5 Form 4 filings on record from December 2020 to March 2023, all as Cheif Financial Officer at Inhibikase Therapeutics (IKT), 2020–2023.
The 6 reported transactions were 4 option or other derivative awards, 1 open-market purchase and 1 conversion.
Counted by filing, the open-market trades come to 1 purchase worth about $3K and no sales.
The only open-market purchase was 3,948 shares of IKT at an average $0.64 on May 19, 2022, about $3K. Twelve months later IKT was up 2%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 | IKT Inhibikase Therapeutics, Inc. | Chief Financial Officer | Buy | 3,948 | $0.64 | $2,542.51 | +8.9% | +30.6% | +1.6% |